Fenclonine

Fenclonine, also known as para-chlorophenylalanine (PCPA), acts as a selective and irreversible inhibitor of tryptophan hydroxylase, which is a rate-limiting enzyme in the biosynthesis of serotonin.[2]

Fenclonine
Clinical data
Other namesCP-10188; Fenclonina; Fencloninum; NSC-77370; Parachlorophenylalanine[1]
ATC code
  • None
Identifiers
IUPAC name
  • (S)-2-Amino-3-(4-chlorophenyl)propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.028.229
Chemical and physical data
FormulaC9H10ClNO
Molar mass183.64 g·mol−1
3D model (JSmol)
Density1.336 g/cm3
Melting point240 °C (464 °F)
Boiling point339.5 °C (643.1 °F)
SMILES
  • Clc1ccc(cc1)CC(C(=O)O)N
InChI
  • InChI=1S/C9H10ClNO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13) Y
  • Key:NIGWMJHCCYYCSF-UHFFFAOYSA-N Y
  (verify)

It has been used experimentally to treat carcinoid syndrome, but the side effects, mostly hypersensitivity reactions and psychiatric disturbances, have prevented development for this use.[3]

The effects of serotonin depletion from fenclonine are so drastic that serotonin cannot even be detected immunohistochemically within the first day after administration of a control dose. Tryptophan hydroxylase activity can be detected neither in cell bodies or nerve terminals. After one week 10% of control values (the baseline extrapolated for the study) had replenished in the raphe nucleus, and after two weeks from initial treatment as much was again detected in the hypothalamus region. Aromatic L-amino acid decarboxylase (AADC) levels were at no time affected.[4]

It is used in scientific research in humans[5] and animals[2] to investigate the effects of serotonin depletion.

See also

References

  1. "Fenclonine" entry in Martindale – The Complete Drug Reference. Maintained in Martindale purely for archival purposes, and is no longer subject to revision and update. (Last reviewed: 2008-08-01; last modified: 2011-09-12). The Royal Pharmaceutical Society of Great Britain 2014
  2. Jouvet M (August 1999). "Sleep and serotonin: an unfinished story". Neuropsychopharmacology. 21 (2 Suppl): 24S–27S. doi:10.1016/S0893-133X(99)00009-3. PMID 10432485.
  3. Kvols LK (December 1986). "Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy". The American Journal of Medicine. 81 (6B): 49–55. doi:10.1016/0002-9343(86)90584-x. PMID 2432781.
  4. Park DH, Stone DM, Baker H, Kim KS, Joh TH (March 1994). "Early induction of rat brain tryptophan hydroxylase (TPH) mRNA following parachlorophenylalanine (PCPA) treatment". Brain Research. Molecular Brain Research. 22 (1–4): 20–8. doi:10.1016/0169-328x(94)90028-0. PMID 8015380.
  5. Ruhé HG, Mason NS, Schene AH (April 2007). "Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies". Molecular Psychiatry. 12 (4): 331–59. doi:10.1038/sj.mp.4001949. PMID 17389902.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.